Benutzer: Gast  Login
Titel:

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

Dokumenttyp:
Journal Article
Autor(en):
Moehler, M; Maderer, A; Thuss-Patience, P C; Brenner, B; Meiler, J; Ettrich, T J; Hofheinz, R-D; Al-Batran, S E; Vogel, A; Mueller, L; Lutz, M P; Lordick, F; Alsina, M; Borchert, K; Greil, R; Eisterer, W; Schad, A; Slotta-Huspenina, J; Van Cutsem, E; Lorenzen, S
Abstract:
BACKGROUND: Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. PATIENTS AND METHODS: Eligible patients with confirmed ESCC that was not curative...     »
Zeitschriftentitel:
Ann Oncol
Jahr:
2020
Band / Volume:
31
Heft / Issue:
2
Seitenangaben Beitrag:
228-235
Volltext / DOI:
doi:10.1016/j.annonc.2019.10.018
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/31959339
Print-ISSN:
0923-7534
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX